We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.ContinueLearn More X
The annual seminar will bring together global pharma and medical device experts in an exploration of this year’s theme: the best solution for the patient from the viewpoint of drugs, containers, and devices.
SHL Group will join the event with a showcase of its advanced drug delivery solutions, which include innovative offerings for high volume/high viscosity formulations designed to meet the needs of next-generation therapies.
For the first time in Japan, SHL will be demonstrating Maggie®, a high-volume cartridge-based auto injector built with the market-proven Needle Isolation Technology (NIT®). SHL will also present its high-volume Molly® 2.25, which offers a shorter development timeline for faster commercialization, and Rotaject®, a state-of-the-art constant force technology that safely delivers viscosities up to several hundred centipoise within seconds.
SHL is pleased to bring its latest portfolio to Japan, a leading market in Asia for self-administered injection devices, and to help biotech and pharma players from around the world to meet their clinical and commercialization needs.
To find out more about SHL’s auto injection devices and digital solutions, stop by the Sola City Conference Center in Tokyo, Japan from May 22-23.
SHL is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as auto injectors and pen injectors. With locations in Taiwan, Sweden and the US, our experienced engineers and designers develop product enhancements and breakthrough drug delivery solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
With over 3,700 staff worldwide, our organization consists of several distinct group companies:
SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.
SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.
SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.
For additional information, visit www.shl.group